Tight control of hyperglycemia in type 2 diabetes mellitus

Insulin

Volumn 1, Issue 4, 2006, Pages 166-172

  Donner, Thomas W ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

exercise; glycemic control; insulin; pharmacotherapy; type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN SENSITIZING AGENT; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ARTICLE; BLOATING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DECREASED APPETITE; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DIARRHEA; DIETARY INTAKE; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG WITHDRAWAL; EDEMA; EXERCISE; FLATULENCE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INDIVIDUALIZATION; INSULIN HYPOGLYCEMIA; INSULIN SENSITIVITY; INSULIN TREATMENT; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; LIVER CELL DAMAGE; LIVER FAILURE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; SIDE EFFECT; TREATMENT FAILURE; TREATMENT PLANNING; UNITED STATES; VOMITING; WEIGHT GAIN;

EID: 33845911773     PISSN: 15570843     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1557-0843(06)80037-0     Document Type: Article

References (60)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 329 (1993) 977-986
2. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Proct. 28 (1995) 103-117
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354:602]. Lancet 352 (1998) 837-853
4. American Diabetes Association. Standards of medical care in diabetes [published correction appears in Diabetes Care. 2005;28:990]. Diabetes Care 28 Suppl 1 (2005) S4-S36
5. American Association of Clinical Endocrinologists, American College of Endocrinology. Medical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes self-management-2002 update. Endocr Proct. 8 Suppl 1 (2002) 40-82
6. Klein B.E., Klein R., McBride P.E., et al. Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes: Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med. 164 (2004) 1917-1924
7. Burchfiel C.M., Reed D.M., Marcus E.B., et al. Association of diabetes mellitus with coronary atherosclerosis and myocardial lesions. An autopsy study from the Honolulu Heart Program. Am J Epidemiol. 137 (1993) 1328-1340
8. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321 (2000) 405-412
9. Klein S., Sheard N.F., Pi-Sunyer X., et al., American Diabetes Association. North American Association for the Study of Obesity; American Society for Clinical Nutrition. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: Rationale and strategies. A statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Am J Clin Nutr. 80 (2004) 257-263
10. Nathan D.M. Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med. 347 (2002) 1342-1349
11. Boule N.G., Haddad E., Kenny G.P., et al. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: A meta-analysis of controlled clinical trials. JAMA 286 (2001) 1218-1227
12. Schneider S.H., Khachadurian A.K., Amoroso L.F., et al. Ten-year experience with an exercise-based outpatient life-style modification program in the treatment of diabetes mellitus. Diabetes Care 15 (1992) 1800-1810
13. Cozma L.S., Luzio S.D., Dunseath G.J., et al. Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal. Diabetes Care 25 (2002) 1271-1276
14. Horton E.S., Clinkingbeard C., Gatlin M., et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 23 (2000) 1660-1665
15. Jovanovic L., Dailey III G., Huang W.C., et al. Repaglinide in type 2 diabetes: A 24-week, fixed-dose efficacy and safety study. J Clin Phormocol. 40 (2000) 49-57
16. Hanefeld M., Bouter K.P., Dickinson S., and Guitard C. Rapid and shortacting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 23 (2000) 202-207
17. van Staa T., Abenhaim L., and Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol. 50 (1997) 735-741
18. Groop L.C. Sulfonylureas in NIDDM. Diabetes Care 15 (1992) 737-754
19. (Suppl). Meinert C.L., Knatterud G.L., Prout T.E., and Klimt C.R. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 19 (1970) 789-830
20. Toombs C.F., Moore T.L., and Shebuski R.J. Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide. Cardioyosc Res. 27 (1993) 617-622
21. Klepzig H., Kober G., Matter C., et al. Sulfonylureas and ischaemic preconditioning: A double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J. 20 (1999) 439-446
22. Simpson S.H., Majumdar S.R., Tsuyuki R.T., et al. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: A population-based cohort study. CMAJ 174 (2006) 169-174
23. Bailey C.J., and Turner R.C. Metformin. N Engl J Med. 334 (1996) 574-579
24. Abbasi F., Chu J.W., McLaughlin T., et al. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism 53 (2004) 159-164
25. Johansen K. Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care 22 (1999) 33-37
26. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published correction appears in Lancet. 1998;352:1558]. Lancet 352 (1998) 854-865
27. DeFronzo R.A. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 131 (1999) 281-303
28. Stumvoll M., Nurjhan N., Perriello G., et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 333 (1995) 550-554
29. Blonde L., Dailey G.E., Jabbour S.A., et al. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: Results of a retrospective cohort study. Curr Med Res Opin. 20 (2004) 565-572
30. Coniff R.F., Shapiro J.A., Robbins D., et al. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study. Diabetes Care 18 (1995) 817-824
31. Johnston P.S., Coniff R.F., Hoogwerf B.J., et al. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care 17 (1994) 20-29
32. Lebovitz H.E. A new oral therapy for diabetes management: Alphaglucosidase inhibition with acarbose. Clin Diabetes 13 (1995) 99-103
33. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 351 (2004) 1106-1118
34. Chiquette E., Ramirez G., and Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med. 164 (2004) 2097-2104
35. Phillips L.S., Grunberger G., Miller E., et al., Rosiglitazone Clinical Trials Study Group. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes [published correction appears in Diabetes Care. 2001;24:973]. Diabetes Care 24 (2001) 308-315
36. Pavo I., Jermendy G., Varkonyi T.T., et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab. 88 (2003) 1637-1645
37. Herz M., Johns D., Reviriego J., et al. A randomized, doubleblind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihy perglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther. 25 (2003) 1074-1095
38. Goldberg R.B., Kendall D.M., Deeg M.A., et al., GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 (2005) 1547-1554
39. Dormandy J.A., Charbonnel B., Eckland D.J., et al., Proactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 366 (2005) 1279-1289
40. Misbin R.I. Evaluating the safety of diabetes drugs: Perspective of a Food and Drug Administration insider. Diabetes Care 28 (2005) 2573-2576
41. Kermani A., and Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc. 78 (2003) 1088-1091
42. Nakamura T., Funahashi T., Yamashita S., et al. Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation-double-blind placebocontrolled trial. Diabetes Res Clin Proct. 54 (2001) 181-190
43. Akazawa S., Sun F., Ito M., et al. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 23 (2000) 1067-1071
44. Drucker D.J. Glucagon-like peptides. Diabetes 47 (1998) 159-169
45. Flint A., Raben A., Astrup A., and Holst J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 101 (1998) 515-520
46. Defronzo R.A., Ratner R.E., Han J., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (2005) 1092-1100
47. Buse J.B., Henry R.R., Han J., et al., Exenatide-1 13 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2628-2635
48. Kendall D.M., Riddle M.C., Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28 (2005) 1083-1091
49. UK Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease [published correction appears in Diabetes. 1996;45:1655]. Diabetes 44 (1995) 1249-1258
50. Ovalle F., and Bell D.S. Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 4 (2002) 56-59
51. Ovalle F., and Bell D.S. Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. Diabetes Care 27 (2004) 2585-2589
52. Tourrel C., Bailbe D., Laconne M., et al. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with Gucagon-like peptide-1 or exendin-4. Diabetes 51 (2002) 1443-1452
53. Mari A., Halseth A., Nanayakkara N., et al. Mathematical modeling shows exenatide improved postprandial beta-cell function in patients with type 2 diabetes treated with metformin or metformin and sulfonylurea. Diabetes 54 Suppl 1 (2005) 482
54. Rosenstock J., Schwartz S.L., Clark Jr. C.M., et al. Basal insulin therapy in type 2 diabetes: 28-Week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24 (2001) 631-636
55. Riddle M.C., Rosenstock J., Gerich J., and Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
56. Garber A.J. Benefits of combination therapy of insulin and oral hypoglycemic agents. Arch Intern Med. 163 (2003) 1781-1782
57. DeWitt D.E., and Hirsch I.B. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review. JAMA 289 (2003) 2254-2264
58. van den Berghe G., Wouters P., Weekers F., et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 345 (2001) 1359-1367
59. Krinsley J.S. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients [published correction appears in Mayo Clin Proc. 2005;80:1101 ]. Mayo Clin Proc. 79 (2004) 992-1000
60. Clement S., Braithwaite S.S., Magee M.F., et al., American Diabetes Association Diabetes in Hospitals Writing Committee. Management of diabetes and hyperglycemia in hospitals [published corrections appear in Diabetes Care. 2004;27:856 and Diabetes Care. 2004;27:1255]. Diabetes Care 27 (2004) 553-591